Point72 Asia Singapore Pte. Ltd. Purchases New Stake in Artivion, Inc. (NYSE:AORT)

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Artivion, Inc. (NYSE:AORT) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,251 shares of the company’s stock, valued at approximately $64,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Barclays PLC boosted its position in Artivion by 346.3% during the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock valued at $1,888,000 after purchasing an additional 54,996 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Artivion by 394.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock valued at $2,606,000 after buying an additional 78,120 shares during the last quarter. Calamos Advisors LLC lifted its holdings in shares of Artivion by 113.7% during the 4th quarter. Calamos Advisors LLC now owns 63,029 shares of the company’s stock valued at $1,802,000 after buying an additional 33,541 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Artivion by 14.4% in the 3rd quarter. Franklin Resources Inc. now owns 21,107 shares of the company’s stock valued at $553,000 after buying an additional 2,663 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Artivion in the fourth quarter worth approximately $194,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Insider Transactions at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 10,548 shares of the firm’s stock in a transaction on Friday, May 9th. The shares were sold at an average price of $29.13, for a total value of $307,263.24. Following the sale, the senior vice president now directly owns 105,332 shares in the company, valued at $3,068,321.16. This trade represents a 9.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Jean F. Holloway sold 5,335 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $145,698.85. Following the transaction, the senior vice president now owns 149,799 shares in the company, valued at approximately $4,091,010.69. The trade was a 3.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 101,347 shares of company stock worth $2,663,486 over the last three months. 7.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

AORT has been the subject of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 target price on shares of Artivion in a research note on Tuesday, May 6th. Citizens Jmp raised shares of Artivion to a “strong-buy” rating in a research report on Tuesday, May 6th. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus lowered their price objective on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $31.40.

Artivion Stock Performance

Shares of AORT opened at $29.46 on Monday. The company has a market capitalization of $1.26 billion, a PE ratio of -1,473.00 and a beta of 1.54. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion, Inc. has a one year low of $21.97 and a one year high of $32.33. The company’s fifty day moving average price is $24.64 and its 200 day moving average price is $27.31.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.06). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The business had revenue of $98.98 million during the quarter, compared to the consensus estimate of $94.81 million. As a group, analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.